Invesco’s aTyr Pharma ATYR Stock Holding History

Invesco’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46,354	Closed	-$36.2K	–	3955
2026 Q1	$36.2K	Buy	46,354 +121	+0.3%	+$102	﹤0.01%	3714
2025 Q4	$36.2K	Buy	46,233 +374	+0.8%	+$307	﹤0.01%	3728
2025 Q3	$33.1K	Sell	45,859 -552,149	-92%	-$2.5M	﹤0.01%	3764
2025 Q2	$3.03M	Buy	+598,008	New	+$2.35M	﹤0.01%	2413
2015 Q3	–	Sell	-18	Closed	-$5K	–	4013
2015 Q2	$5K	Buy	+18	New	+$5.59K	﹤0.01%	4221

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco's ATYR Position: Q2 2026 in Review

Invesco sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 46,354 shares — an estimated $36.2K sold.

Invesco first reported a position in ATYR in Q2 2015 and held it in 5 quarters. The position peaked at $3.03M in Q2 2025. 89 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Invesco reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
Invesco sold 46,354 aTyr Pharma shares in Q2 2026, an estimated $36.2K.
Invesco first reported a position in aTyr Pharma in Q2 2015 and held it in 5 quarters.
Invesco's aTyr Pharma position peaked at $3.03M in Q2 2025.
89 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.